Literature DB >> 7512172

Indomethacin potentiates the induction of HL60 differentiation to neutrophils, by retinoic acid and granulocyte colony-stimulating factor, and to monocytes, by vitamin D3.

C M Bunce1, P J French, J Durham, R A Stockley, R H Michell, G Brown.   

Abstract

We have confirmed previous observations that HL60 cells treated with a combination of 10 nM retinoic acid (RA), and 30 ng/ml granulocyte colony-stimulating factor (G-CSF) differentiate efficiently towards neutrophils, as characterized by their growth arrest and acquisition of phagocytic ability. Such low concentrations of RA alone provoked only a small proportion of HL60 cells to differentiate, and G-CSF alone provoked no differentiation. In the presence of 30 microM indomethacin (an inhibitor of the enzyme cyclooxygenase that catalyses the first step of prostanoid synthesis), the onset of differentiation provoked by RA plus G-CSF was more rapid, but the final proportion of mature cells was unchanged. Indomethacin also potentiated the growth arrest and differentiation of cells in response to 10 nM RA alone. Although the potentiating effect of indomethacin on RA-induced differentiation occurred at several indomethacin and RA concentrations, it was only apparent when the RA concentration used was alone sufficient to induce a small proportion of cells to differentiate. Indomethacin shifted the G-CSF dose-response curve of cells treated with 10 nM RA to lower G-CSF concentrations. 1 alpha,25-dihydroxy vitamin D3 (VitD3) induces HL60 cells to differentiate to monocytes and indomethacin also potentiated the differentiation of HL60 cells in response to low doses of VitD3 5,8,11-eicosatriynoic acid, an inhibitor of 5-lipoxygenase and 12-lipoxygenase, neither potentiated neutrophil differentiation of HL60 cells, nor prevented indomethacin potentiation of the differentiation of RA-primed cells. Treatment of cells with dexamethasone, a steroid whose effects include inhibition of arachidonate mobilization by phospholipase A2, potentiated RA-primed neutrophil differentiation in a manner similar to indomethacin. These observations suggest that an arachidonate metabolite formed downstream of cyclooxygenase suppresses differentiation of HL60 cells both to neutrophils and monocytes, probably by inhibiting some event essential to commitment to differentiation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7512172

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  12 in total

Review 1.  Use of HL-60 cell line to measure opsonic capacity of pneumococcal antibodies.

Authors:  R A Fleck; S Romero-Steiner; M H Nahm
Journal:  Clin Diagn Lab Immunol       Date:  2005-01

2.  Isocitrate dehydrogenase 2 inhibitor enasidenib synergizes daunorubicin cytotoxicity by targeting aldo-keto reductase 1C3 and ATP-binding cassette transporters.

Authors:  Anselm Morell; Youssif Budagaga; Dimitrios Vagiannis; Yu Zhang; Lenka Laštovičková; Eva Novotná; Andrew Haddad; Melodie Haddad; Ramon Portillo; Jakub Hofman; Vladimír Wsól
Journal:  Arch Toxicol       Date:  2022-08-16       Impact factor: 6.168

3.  Optimization of nb-4 and hl-60 differentiation for use in opsonophagocytosis assays.

Authors:  Roland A Fleck; Harpinder Athwal; Jane A Bygraves; David J Hockley; Ian M Feavers; Glyn N Stacey
Journal:  In Vitro Cell Dev Biol Anim       Date:  2003 May-Jun       Impact factor: 2.416

Review 4.  Tretinoin. A review of its pharmacodynamic and pharmacokinetic properties and use in the management of acute promyelocytic leukaemia.

Authors:  J C Gillis; K L Goa
Journal:  Drugs       Date:  1995-11       Impact factor: 9.546

5.  Induction of differentiation of human leukemia cells by combinations of COX inhibitors and 1,25-dihydroxyvitamin D3 involves Raf1 but not Erk 1/2 signaling.

Authors:  Farnaz Jamshidi; Jing Zhang; Jonathan S Harrison; Xuening Wang; George P Studzinski
Journal:  Cell Cycle       Date:  2008-01-14       Impact factor: 4.534

6.  Exposure of human breast cancer cells to the anti-inflammatory agent indomethacin alters choline phospholipid metabolites and Nm23 expression.

Authors:  Kshama Natarajan; Noriko Mori; Dmitri Artemov; Zaver M Bhujwalla
Journal:  Neoplasia       Date:  2002 Sep-Oct       Impact factor: 5.715

7.  Selective AKR1C3 inhibitors do not recapitulate the anti-leukaemic activities of the pan-AKR1C inhibitor medroxyprogesterone acetate.

Authors:  F Khanim; N Davies; P Veliça; R Hayden; J Ride; C Pararasa; M G Chong; U Gunther; N Veerapen; P Winn; R Farmer; E Trivier; L Rigoreau; M Drayson; C Bunce
Journal:  Br J Cancer       Date:  2014-02-25       Impact factor: 7.640

8.  AKR1C enzymes sustain therapy resistance in paediatric T-ALL.

Authors:  Roberta Bortolozzi; Silvia Bresolin; Elena Rampazzo; Maddalena Paganin; Francesca Maule; Elena Mariotto; Daniele Boso; Sonia Minuzzo; Valentina Agnusdei; Giampietro Viola; Geertruy Te Kronnie; Giovanni Cazzaniga; Giuseppe Basso; Luca Persano
Journal:  Br J Cancer       Date:  2018-03-08       Impact factor: 7.640

9.  Phagocytosis of Streptococcus pyogenes by all-trans retinoic acid-differentiated HL-60 cells: roles of azurophilic granules and NADPH oxidase.

Authors:  Pontus Nordenfelt; Susanne Bauer; Per Lönnbro; Hans Tapper
Journal:  PLoS One       Date:  2009-10-06       Impact factor: 3.240

10.  Retinoid differentiation therapy for common types of acute myeloid leukemia.

Authors:  Geoffrey Brown; Philip Hughes
Journal:  Leuk Res Treatment       Date:  2012-06-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.